455 related articles for article (PubMed ID: 29048579)
21. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
22. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
24. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
25. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
26. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
Asano N; Saito M; Kobayashi E; Morii T; Kikuta K; Watanabe I; Anazawa U; Takeuchi K; Suzuki Y; Susa M; Nishimoto K; Ishii R; Miyazaki N; Mrioka H; Kawai A; Horiuchi K; Nakayama R
Ann Surg Oncol; 2022 Jun; 29(6):3992-4000. PubMed ID: 35175454
[TBL] [Abstract][Full Text] [Related]
27. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract][Full Text] [Related]
28. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
29. Radiological findings of denosumab treatment for giant cell tumours of bone.
van Langevelde K; McCarthy CL
Skeletal Radiol; 2020 Sep; 49(9):1345-1358. PubMed ID: 32335707
[TBL] [Abstract][Full Text] [Related]
30. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
von Borstel D; A Taguibao R; A Strle N; E Burns J
Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
[TBL] [Abstract][Full Text] [Related]
31. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
[TBL] [Abstract][Full Text] [Related]
32. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
33. Symplastic/pseudoanaplastic giant cell tumor of the bone.
Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
[TBL] [Abstract][Full Text] [Related]
34. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.
Rekhi B; Verma V; Gulia A; Jambhekar NA; Desai S; Juvekar SL; Bajpai J; Puri A
Pathol Oncol Res; 2017 Jan; 23(1):157-164. PubMed ID: 27722984
[TBL] [Abstract][Full Text] [Related]
36. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature.
Luengo-Alonso G; Mellado-Romero M; Shemesh S; Ramos-Pascua L; Pretell-Mazzini J
Arch Orthop Trauma Surg; 2019 Oct; 139(10):1339-1349. PubMed ID: 30877429
[TBL] [Abstract][Full Text] [Related]
37. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
38. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
39. Giant Cell Tumor of Bone of the First Rib Successfully Treated with Combined Preoperative Denosumab Therapy and Surgery via a Transmanubrial Approach.
Matsunobu T; Maekawa A; Nabeshima A; Sakamoto A; Tamura K; Odate S; Iwamoto Y
Am J Case Rep; 2021 Jun; 22():e931796. PubMed ID: 34059614
[TBL] [Abstract][Full Text] [Related]
40. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]